Clinical Experience With Three-Factor Prothrombin Complex Concentrate to Reverse Warfarin Anticoagulation in Intracranial Hemorrhage | Zendy

Jeffrey A. Switzer | Zendy; Jody Rocker | Zendy; Phillip Mohorn | Zendy; Jennifer L. Waller | Zendy; Douglas Hughes | Zendy; Askiel Bruno | Zendy; Fenwick T. Nichols | Zendy; David C. Hess | Zendy; Kavita Natarajan | Zendy; Susan C. Fagan | Zendy

Open Access

Clinical Experience With Three-Factor Prothrombin Complex Concentrate to Reverse Warfarin Anticoagulation in Intracranial Hemorrhage

Author(s) -

Jeffrey A. Switzer,

Jody Rocker,

Phillip Mohorn,

Jennifer L. Waller,

Douglas Hughes,

Askiel Bruno,

Fenwick T. Nichols,

David C. Hess,

Kavita Natarajan,

Susan C. Fagan

Publication year - 2012

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.112.661454

Subject(s) - medicine , fresh frozen plasma , warfarin , prothrombin complex concentrate , concomitant , coagulopathy , adverse effect , stroke (engine) , anesthesia , prothrombin time , intraparenchymal hemorrhage , surgery , subarachnoid hemorrhage , atrial fibrillation , mechanical engineering , platelet , engineering

The effectiveness of prothrombin complex concentrate (PCC) products available in the United States that contain low levels of factor VII (3-factor PCC) has not been tested. The purpose of this study was to review our experience with 3-factor PCC (Profilnine) in the setting of warfarin-associated intracranial hemorrhage (wICH).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research